Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is 43% above its 5-year average of 70.00%, near the high end of its 5-year range (-3431.79%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 116.49% above its 12-month average of -606.36%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
-606.36%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
70.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+116.49%
CURRENT VS 3Y AVG
0.00%
CURRENT VS 5Y AVG
+42.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.51%
median of 389 covered companies
CURRENT VS SECTOR MEDIAN
+115.01%
vs the sector median at left
Cardio Diagnostics Holdings, Inc.
Market Cap
$6.10M
Gross Margin
100.00%
TTM Avg
-606.36%
3Y Avg
100.00%
5Y Avg
70.00%
Market Cap
$6.09M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-2.09%
Market Cap
$6.03M
Gross Margin
-1.29%
TTM Avg
-3.77%
3Y Avg
16.02%
5Y Avg
20.70%
Market Cap
$6.44M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.63M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.72M
Gross Margin
80.62%
TTM Avg
90.31%
3Y Avg
-419.28%
5Y Avg
-4158.68%
Market Cap
$6.74M
Gross Margin
-291.27%
TTM Avg
-237.54%
3Y Avg
-120.88%
5Y Avg
-89.07%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | $6.10M | 100.00% | -606.36% | 100.00% | 70.00% |
| Femasys Inc. (FEMY)vs › | $6.10M | 61.96% | 64.25% | 64.10% | 65.91% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | 0.00% | 0.00% | 0.00% | -2.09% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | -1.29% | -3.77% | 16.02% | 20.70% |
| Biomerica, Inc. (BMRA)vs › | $6.34M | 8.09% | 8.76% | 9.29% | 9.67% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | 0.00% | 0.00% | 0.00% | 0.00% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | 80.62% | 90.31% | -419.28% | -4158.68% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -291.27% | -237.54% | -120.88% | -89.07% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | -3431.79% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
